Glucagon-like peptide-1 (GLP-1) compounds have emerged as a compelling therapeutic strategy for managing metabolic conditions. These naturally occurring substances are secreted by the gut in response to meal intake, stimulating insulin release and suppressing glucagon output. GLP-1 derivatives demonstrate promising therapeutic outcomes in treating